Dimerix Past Earnings Performance
Past criteria checks 0/6
Dimerix's earnings have been declining at an average annual rate of -29.5%, while the Biotechs industry saw earnings growing at 13.2% annually. Revenues have been growing at an average rate of 16.8% per year.
Key information
-29.5%
Earnings growth rate
-10.1%
EPS growth rate
| Biotechs Industry Growth | 9.6% |
| Revenue growth rate | 16.8% |
| Return on equity | -93.9% |
| Net Margin | -2,926.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Dimerix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -17 | 5 | 21 |
| 31 Mar 24 | 0 | -14 | 4 | 19 |
| 31 Dec 23 | 9 | -11 | 3 | 17 |
| 30 Sep 23 | 9 | -12 | 3 | 19 |
| 30 Jun 23 | 0 | -14 | 2 | 20 |
| 31 Mar 23 | 3 | -14 | 2 | 19 |
| 31 Dec 22 | 6 | -14 | 2 | 18 |
| 30 Sep 22 | 6 | -12 | 2 | 16 |
| 30 Jun 22 | 6 | -10 | 3 | 14 |
| 31 Mar 22 | 5 | -10 | 2 | 13 |
| 31 Dec 21 | 4 | -9 | 2 | 11 |
| 30 Sep 21 | 4 | -7 | 2 | 10 |
| 30 Jun 21 | 4 | -6 | 2 | 9 |
| 31 Mar 21 | 3 | -6 | 1 | 8 |
| 31 Dec 20 | 2 | -6 | 1 | 7 |
| 30 Sep 20 | 2 | -5 | 1 | 6 |
| 30 Jun 20 | 2 | -4 | 1 | 6 |
| 31 Mar 20 | 2 | -4 | 1 | 5 |
| 31 Dec 19 | 1 | -4 | 1 | 4 |
| 30 Sep 19 | 1 | -4 | 1 | 3 |
| 30 Jun 19 | 1 | -3 | 1 | 3 |
| 31 Mar 19 | 1 | -3 | 1 | 3 |
| 31 Dec 18 | 1 | -3 | 1 | 3 |
| 30 Sep 18 | 1 | -3 | 2 | 3 |
| 30 Jun 18 | 1 | -3 | 2 | 2 |
| 31 Mar 18 | 1 | -3 | 2 | 2 |
| 31 Dec 17 | 1 | -3 | 2 | 1 |
| 30 Sep 17 | 1 | -2 | 2 | 1 |
| 30 Jun 17 | 1 | -2 | 1 | 1 |
| 31 Mar 17 | 1 | -2 | 1 | 1 |
| 31 Dec 16 | 1 | -2 | 1 | 1 |
| 30 Sep 16 | 1 | -3 | 1 | 1 |
| 30 Jun 16 | 1 | -5 | 1 | 1 |
| 31 Mar 16 | 0 | -5 | 1 | 0 |
| 31 Dec 15 | 0 | -5 | 1 | 0 |
| 30 Sep 15 | 0 | -3 | 1 | 0 |
| 30 Jun 15 | 0 | -1 | 1 | 0 |
| 30 Apr 14 | 0 | 0 | 0 | 0 |
Quality Earnings: DXB is currently unprofitable.
Growing Profit Margin: DXB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DXB is unprofitable, and losses have increased over the past 5 years at a rate of 29.5% per year.
Accelerating Growth: Unable to compare DXB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DXB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: DXB has a negative Return on Equity (-93.89%), as it is currently unprofitable.